MCID: NRB001
MIFTS: 73

Neuroblastoma

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neuroblastoma

MalaCards integrated aliases for Neuroblastoma:

Name: Neuroblastoma 53 12 72 49 24 55 36 28 13 40 41 14 69
Neuroblastoma 1 53 71 28
Nb 49 24
Neuroblastoma, Susceptibility to, 1 53
Neuroblastoma, Susceptibility to 53
Central Neuroblastoma 69
Nblst1 71

Characteristics:

Orphanet epidemiological data:

55
neuroblastoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Childhood; Age of death: adolescent,late childhood;

OMIM:

53
Inheritance:
autosomal dominant
isolated cases

Miscellaneous:
genetic heterogeneity
incomplete penetrance
mean age of onset 14-24 months
highly variable clinical phenotype
symptoms vary according to location of tumor
spontaneous tumor regression may occur
usually sporadic, but 1-2% of cases are familial
n-myc oncogene amplification is associated with poor prognosis


HPO:

31
neuroblastoma:
Onset and clinical course incomplete penetrance
Inheritance heterogeneous autosomal dominant inheritance sporadic


Classifications:

Orphanet: 55  
Rare neurological diseases


Summaries for Neuroblastoma

OMIM : 53 Neuroblastoma is the most common childhood cancer diagnosed before the age of 1 year, and accounts for 10 to 15% of all cancer deaths in children. Some patients inherit a genetic predisposition to neuroblastoma due to germline mutations, whereas others develop sporadic disease that may result from either germline or somatic mutations. Neuroblastoma tumors are derived from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system (Roberts et al., 1998; Eng, 2008). Histopathologically, neuroblastoma can range in type from the most aggressive form, neuroblastoma, composed entirely of immature neural precursor cells, to ganglioneuroma, composed entirely of mature neural tissue. The most important prognostic factor for patients with neuroblastoma is the extent of the tumor at the time of diagnosis (Roberts et al., 1998). Neuroblastoma can also be part of cancer-prone syndromes, such as paragangliomas (see, e.g., PGL4; 115310). (256700)

MalaCards based summary : Neuroblastoma, also known as neuroblastoma 1, is related to nodular ganglioneuroblastoma and hereditary wilms' tumor, and has symptoms including neoplasm of the nervous system, elevated urinary catecholamines and ataxia. An important gene associated with Neuroblastoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Unituxin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, bone and bone marrow.

UniProtKB/Swiss-Prot : 71 Neuroblastoma 1: A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.

NIH Rare Diseases : 49 Neuroblastoma is a tumor that develops from a nerve in a child, usually before the age of 5.  It occurs in the abdomen near the adrenal glands, but it can also occur in other parts of the body.  It is considered an aggressive tumor because it often spreads to other parts of the body (metastasizes).  The symptoms of a neuroblastoma may include a lump in the abdomen, pain, diarrhea, or generally feeling unwell.  It affects one out of 100,000 children.  The exact cause of this tumor is not yet known.  Neuroblastoma may be diagnosed by physical examination; specific blood tests; imaging tests such as x-rays, magnetic resonance imaging (MRI), or computed tomography (CT) scans; and a biopsy.  Treatment depends on the size and location of the tumor within the body, as well as the child’s age. Surgery is often the first step of treatment, and may be followed by chemotherapy, radiation therapy, or a stem cell transplant in more severe cases. Last updated: 10/7/2011

MedlinePlus : 40 Neuroblastoma is a cancer that forms in your nerve tissue. It usually begins in the adrenal glands, which sit atop your kidneys. It may also begin in your neck, chest or spinal cord. The cancer often begins in early childhood. Sometimes it begins before a child is born. By the time doctors find the cancer, it has usually spread to other parts of the body. The most common symptoms are A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part Treatments include surgery, radiation therapy, chemotherapy, biologic therapy, or a combination. Biologic therapy boosts your body's own ability to fight cancer. Sometimes before giving treatment, doctors wait to see whether symptoms get worse. This is called watchful waiting. NIH: National Cancer Institute

Genetics Home Reference : 24 Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. Most commonly, the tumor originates in the nerve tissue of the adrenal gland located above each kidney. Other common sites for tumors to form include the nerve tissue in the abdomen, chest, neck, or pelvis. Neuroblastoma can spread (metastasize) to other parts of the body such as the bones, liver, or skin.

Disease Ontology : 12 An autonomic nervous system neoplasm that derives from immature nerve cells.

Wikipedia : 72 Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently... more...

Related Diseases for Neuroblastoma

Diseases in the Neuroblastoma family:

Neuroblastoma 2 Neuroblastoma 3
Neuroblastoma 4 Neuroblastoma 5
Neuroblastoma 6 Neuroblastoma 7

Diseases related to Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 340)
# Related Disease Score Top Affiliating Genes
1 nodular ganglioneuroblastoma 30.3 ALK MYCN
2 hereditary wilms' tumor 30.2 ALK PHOX2B
3 olfactory neuroblastoma 12.3
4 neuroblastoma 2 12.3
5 neuroblastoma 3 12.2
6 cervical neuroblastoma 12.2
7 cerebral neuroblastoma 12.1
8 adrenal neuroblastoma 12.1
9 nijmegen breakage syndrome 12.1
10 differentiating neuroblastoma 12.0
11 extracranial neuroblastoma 12.0
12 retroperitoneal neuroblastoma 12.0
13 renal cell carcinoma associated with neuroblastoma 12.0
14 neuroblastoma breakpoint family, member 17, pseudogene 11.9
15 neuroblastoma 4 11.9
16 neuroblastoma 5 11.9
17 neuroblastoma 6 11.9
18 nasal cavity olfactory neuroblastoma 11.9
19 spinal cord neuroblastoma 11.9
20 neuroblastoma 7 11.8
21 mediastinum neuroblastoma 11.8
22 nicolaides-baraitser syndrome 11.7
23 retinoblastoma 11.6
24 opsoclonus-myoclonus syndrome 11.3
25 ganglioneuroblastoma 11.3
26 medulloblastoma 11.2
27 central hypoventilation syndrome, congenital 11.2
28 weaver syndrome 11.2
29 nijmegen breakage syndrome-like disorder 11.1
30 adrenal carcinoma 11.1
31 autonomic nervous system neoplasm 10.9 ALK MYCN MYCNOS NBPF11 NRAS PHOX2B
32 wilms tumor 1 10.9
33 simpson-golabi-behmel syndrome 10.9
34 peripheral nervous system neoplasm 10.8 ALK MYCN NBPF11 NRAS PHOX2B
35 cohen syndrome 10.8
36 hirschsprung disease ganglioneuroblastoma 10.8
37 brain cancer 10.8 ALK MYCN TP73
38 feingold syndrome 1 10.7 MYCN NBAS
39 peripheral t-cell lymphoma 10.6 ALK NME1
40 neuronitis 10.5
41 glioma 10.4
42 charcot-marie-tooth disease, demyelinating, type 1d 10.4 KIF1B MYCN
43 cerebritis 10.3
44 ganglioneuroma 10.3
45 hypoxia 10.3
46 wilms tumor 6 10.1
47 cervicitis 10.1
48 aging 10.1
49 sarcoma 10.1
50 endotheliitis 10.1

Graphical network of the top 20 diseases related to Neuroblastoma:



Diseases related to Neuroblastoma

Symptoms & Phenotypes for Neuroblastoma

Symptoms via clinical synopsis from OMIM:

53
NeurologicCentralNervousSystem:
ataxia
myoclonus
opsoclonus
spinal cord compression
paraneoplastic syndromes

Abdomen:
abdominal pain
palpable abdominal mass
abdominal mass with calcifications on radiology

Neoplasia:
ganglioneuroma
ganglioneuroblastoma
neuroblastoma, arises anywhere along the sympathetic chain (including intracranially)
adrenal glands are most common site

HeadAndNeckEyes:
horner's syndrome
periorbital ecchymoses (soft tissue involvement)

Chest:
mediastinal mass with calcifications on radiology

Skeletal:
bone pain (with metastatic disease)

Hematology:
anemia (with bone marrow involvement)

MetabolicFeatures:
fever

GrowthOther:
failure to thrive

GrowthWeight:
weight loss (with disseminated disease)

CardiovascularVascular:
hypertension (compression of renal arteries)

AbdomenGastrointestinal:
diarrhea (due to vasoactive intestinal peptide)

SkinNailsHairSkin:
bluish skin nodules

LaboratoryAbnormalities:
increased urinary catecholamines
increased urinary homovanillic acid (hva)
increased urinary vanillylmandelic acid (vma)
increased urinary dopamine
tumor may secrete vasoactive intestinal peptide (vip)


Clinical features from OMIM:

256700

Human phenotypes related to Neuroblastoma:

55 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the nervous system 55 31 hallmark (90%) Very frequent (99-80%) HP:0004375
2 elevated urinary catecholamines 55 31 hallmark (90%) Very frequent (99-80%) HP:0011976
3 ataxia 31 HP:0001251
4 fever 31 HP:0001945
5 myoclonus 31 HP:0001336
6 abdominal pain 31 HP:0002027
7 diarrhea 31 HP:0002014
8 bone pain 31 HP:0002653
9 hypertension 31 HP:0000822
10 failure to thrive 31 HP:0001508
11 anemia 31 HP:0001903
12 weight loss 31 HP:0001824
13 abnormality of the thorax 31 HP:0000765
14 neuroblastoma 31 HP:0003006
15 skin nodule 31 HP:0200036
16 ganglioneuroma 31 HP:0003005
17 horner syndrome 31 HP:0002277
18 ganglioneuroblastoma 31 HP:0006747
19 opsoclonus 31 HP:0010543
20 spinal cord compression 31 HP:0002176
21 elevated urinary dopamine 31 HP:0011979
22 elevated urinary homovanillic acid 31 HP:0011977
23 elevated urinary vanillylmandelic acid 31 HP:0011978

UMLS symptoms related to Neuroblastoma:


sleeplessness, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

Drugs & Therapeutics for Neuroblastoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Unituxin 17 45 DINUTUXIMAB United Therapeutics March 2015

Drugs for Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 403)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
3
Itraconazole Approved, Investigational Phase 4,Phase 3 84625-61-6 55283
4
Nicotine Approved Phase 4 54-11-5 89594 942
5 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
6 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
8 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Hormones Phase 4,Phase 3,Phase 2,Phase 1
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
13 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
14 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
15 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
16 Hydroxyitraconazole Phase 4,Phase 3
17 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
18 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
19
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
20
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
21
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
22
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
23
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
24
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
25
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
26
Melphalan Approved Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 460612 4053
27
Isotretinoin Approved Phase 3,Phase 1,Phase 2 4759-48-2 5282379 5538
28
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
29
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
30
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
31
Vindesine Approved, Investigational Phase 3,Phase 2 53643-48-4, 59917-39-4 40839
32
Aldesleukin Approved Phase 3,Phase 2,Phase 1 110942-02-4, 85898-30-2
33 Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 52-24-4 5453
34
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
35
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
36
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
37
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
38
Captopril Approved Phase 3 62571-86-2 44093
39
Palivizumab Approved, Investigational Phase 3 188039-54-5
40
Ribavirin Approved Phase 3 36791-04-5 37542
41
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
42
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
43
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
44
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
45
Iodine Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 7553-56-2 807
46
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
47
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
48
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
49
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
50
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946

Interventional clinical trials:

(show top 50) (show all 537)

# Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
4 Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma Unknown status NCT00276731 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
5 Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma Unknown status NCT00416676 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
6 Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant Unknown status NCT00417053 Phase 3 busulfan;carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide phosphate;melphalan;vincristine sulfate
7 Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma Unknown status NCT00030719 Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;isotretinoin;melphalan;vincristine sulfate
8 Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma Unknown status NCT00410631 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate;vindesine
9 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
10 Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients Completed NCT03042429 Phase 3 Cycles N8, N5 and N6;Cycles N5 and N6
11 Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma Completed NCT00365755 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;melphalan;vincristine sulfate
12 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed NCT00499616 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride;Isotretinoin;Filgrastim
13 Surgery in Treating Children With Neuroblastoma Completed NCT00003119 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
14 Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma Completed NCT00025428 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
15 Combination Chemotherapy in Treating Children With Neuroblastoma Completed NCT00003093 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
16 Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma Completed NCT00002802 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;mesna;vincristine sulfate;vindesine
17 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma Completed NCT00004188 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate
18 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
19 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Completed NCT00033293 Phase 3 cyclophosphamide;prednisone;Corticotropin-Releasing Hormone
20 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Completed NCT01041638 Phase 3 Isotretinoin
21 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Completed NCT00026312 Phase 3 Isotretinoin
22 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed NCT00567567 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate Liposome
23 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
24 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
25 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
26 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
27 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
28 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
29 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
30 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
31 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
32 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
33 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
34 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
35 Naxitamab for Neuroblastoma With Osteomedullary Disease Recruiting NCT03363373 Phase 3
36 High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN) Recruiting NCT01704716 Phase 3 Vincristine;Aldesleukin;ch14.18/CHO;Carboplatin;Etoposide;Cisplatin;Cyclophosphamide;Doxorubicin;G-CSF;Busulfan;Melphalan
37 Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Etoposide;Cyclophosphamide;Doxorubicin Hydrochloride
38 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
39 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
40 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 cisplatin;cyclophosphamide;etoposide;carboplatin;vincristine sulfate;thiotepa
41 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
42 131I-burtomab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Not yet recruiting NCT03275402 Phase 2, Phase 3
43 Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Not yet recruiting NCT03126916 Phase 3 Busulfan;Carboplatin;Cisplatin;Crizotinib;Cyclophosphamide;Dexrazoxane Hydrochloride;Doxorubicin Hydrochloride;Etoposide Phosphate;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate
44 Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma Terminated NCT00539500 Phase 2, Phase 3 Carboplatin;Etoposide;Melphalan
45 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
46 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
47 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
48 Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma Unknown status NCT01156350 Phase 2 Busulfan - Fludarabine - TBI
49 Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma Unknown status NCT00392340 Phase 2 doxorubicin hydrochloride;topotecan hydrochloride;vincristine sulfate
50 Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation Unknown status NCT00003743 Phase 2

Search NIH Clinical Center for Neuroblastoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: neuroblastoma

Genetic Tests for Neuroblastoma

Genetic tests related to Neuroblastoma:

# Genetic test Affiliating Genes
1 Neuroblastoma 28 KIF1B NME1
2 Neuroblastoma 1 28

Anatomical Context for Neuroblastoma

MalaCards organs/tissues related to Neuroblastoma:

38
Adrenal Gland, Bone, Bone Marrow, Brain, Skin, T Cells, Kidney

Publications for Neuroblastoma

Articles related to Neuroblastoma:

(show top 50) (show all 4957)
# Title Authors Year
1
Rare MYC-amplified Neuroblastoma With Large Cell Histology. ( 29426276 )
2018
2
Different inhibitory effects on the proliferation and apoptosis of human and laboratory Borna disease virusa89infected human neuroblastoma SHa89SY5Y cells inA vitro. ( 29115502 )
2018
3
MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. ( 29445162 )
2018
4
In situ monitoring of PTHLH secretion in neuroblastoma cells cultured onto nanoporous membranes. ( 29438908 )
2018
5
A physiologically relevant 3D collagen-based scaffold - neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models. ( 29447961 )
2018
6
Neuroprotective effects of seaweeds against 6-hydroxidopamine-induced cell death on an in vitro human neuroblastoma model. ( 29444677 )
2018
7
Scavenger receptor class B type 1 regulates neuroblastoma cell proliferation, migration and invasion. ( 29128352 )
2018
8
Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth. ( 29242118 )
2018
9
Neuroprotective Effects of Phenolic and Carboxylic Acids on Oxidative Stress-Induced Toxicity in Human Neuroblastoma SH-SY5Y Cells. ( 29417471 )
2018
10
PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4. ( 29452418 )
2018
11
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved? ( 29439882 )
2018
12
Olfactory Neuroblastoma. ( 29411144 )
2018
13
Vandetanib inhibits cisplatina89resistant neuroblastoma tumor growth and invasion. ( 29436676 )
2018
14
Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. ( 29427030 )
2018
15
Comparative gene expression profiling of human metallothionein-3 up-regulation in neuroblastoma cells and its impact on susceptibility to cisplatin. ( 29435113 )
2018
16
Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. ( 29376112 )
2018
17
Intratumoral Delivery of Interferon I^-secreting MSCs Repolarizes Tumor-Associated Macrophages and Suppresses Neuroblastoma Proliferation In Vivo. ( 29430789 )
2018
18
<i>MYCN</i> Amplification Promotes Enhancer Invasion in Neuroblastoma. ( 29439151 )
2018
19
Origin and initiation mechanisms of neuroblastoma. ( 29445860 )
2018
20
PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma. ( 29440296 )
2018
21
Incidental neuroblastoma with bilateral retinoblastoma: what are the chances? ( 29336617 )
2018
22
Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SHSY-5Y by inhibiting PI3K/Akt-dependent glycolysis. ( 29426376 )
2018
23
Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-I_B activation. ( 29423589 )
2018
24
Neuroimmunology of OMS and ANNA-1/anti-Hu paraneoplastic syndromes in a child with neuroblastoma. ( 29318181 )
2018
25
Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. ( 29135842 )
2018
26
Survival outcome of intermediate risk neuroblastoma at Children Cancer Hospital Egypt. ( 29428371 )
2018
27
Triptolide inhibits proliferation and migration of human neuroblastoma SH-SY5Y cells by up-regulating microRNA-181a. ( 29426375 )
2018
28
Ectopic Cushing's syndrome secondary to olfactory neuroblastoma. ( 29340776 )
2018
29
Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma. ( 28465480 )
2017
30
Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells. ( 28065858 )
2017
31
PPARI^ coactivator-1I+ (PGC-1I+) protects neuroblastoma cells against amyloid-beta (AI^) induced cell death and neuroinflammation via NF-I_B pathway. ( 28946859 )
2017
32
Immunohistochemical analysis of PDK1, PHD3 and HIF-1I+ expression defines the hypoxic status of neuroblastoma tumors. ( 29117193 )
2017
33
The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. ( 28061552 )
2017
34
Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. ( 28521076 )
2017
35
Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma. ( 28545128 )
2017
36
Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma. ( 28525978 )
2017
37
Transcription instability in high-risk neuroblastoma is associated with a global perturbation of chromatin domains. ( 28941026 )
2017
38
Bilateral Cystic Adrenal Neuroblastoma with Cystic Liver metastasis. ( 28163998 )
2017
39
Assessment of frozen section margin analysis during olfactory neuroblastoma surgery. ( 28349538 )
2017
40
Molecular galactose-galectin association in neuroblastoma cells: an unconventional tool for qualitative/quantitative screening. ( 28066995 )
2017
41
ARID1B alterations identify aggressive tumors in neuroblastoma. ( 28521285 )
2017
42
VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells. ( 28945187 )
2017
43
Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway. ( 28783174 )
2017
44
Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation. ( 28174207 )
2017
45
LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. ( 28867147 )
2017
46
Palmitic acid stimulates energy metabolism and inhibits insulin/PI3K/AKT signaling in differentiated human neuroblastoma cells: The role of mTOR activation and mitochondrial ROS production. ( 28919254 )
2017
47
Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma. ( 27270431 )
2017
48
Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications. ( 28775129 )
2017
49
In this issue - July 2017: RHDV vaccine protects against both strains of virus a88A^a88 Olfactory neuroblastoma in a Malamute a88A^a88 Coincidental conditions affecting dysphagia in a Miniature Poodle a88A^a88 Support for storing high-quality bovine colostrum a88A^a88 Sarcoptic mange in koalas a88A^a88 Renal oxalosis in rare Gilbert's potoroos a88A^a88 Novel trypanosomes in a little red flying fox. ( 28653384 )
2017
50
Correction: Intermittent Hypoxia Effect on Osteoclastogenesis Stimulated by Neuroblastoma Cells. ( 28085942 )
2017

Variations for Neuroblastoma

ClinVar genetic disease variations for Neuroblastoma:

6 (show all 45)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
2 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
3 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
4 ALK NM_004304.4(ALK): c.3824G> A (p.Arg1275Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994087 GRCh37 Chromosome 2, 29432664: 29432664
5 ALK NM_004304.4(ALK): c.3383G> C (p.Gly1128Ala) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994088 GRCh37 Chromosome 2, 29445450: 29445450
6 ALK NM_004304.4(ALK): c.3575G> C (p.Arg1192Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994089 GRCh37 Chromosome 2, 29443642: 29443642
7 ALK NM_004304.4(ALK): c.3452C> T (p.Thr1151Met) single nucleotide variant Pathogenic,risk factor rs113994091 GRCh37 Chromosome 2, 29445273: 29445273
8 ALK NM_004304.4(ALK): c.3749T> C (p.Ile1250Thr) single nucleotide variant Pathogenic/Likely pathogenic rs113994092 GRCh37 Chromosome 2, 29432739: 29432739
9 ALK NM_004304.4(ALK): c.3520T> G (p.Phe1174Val) single nucleotide variant Pathogenic rs281864719 GRCh37 Chromosome 2, 29443697: 29443697
10 ALK NM_004304.4(ALK): c.3733T> G (p.Phe1245Val) single nucleotide variant Pathogenic rs281864720 GRCh37 Chromosome 2, 29436860: 29436860
11 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
12 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
13 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Likely pathogenic rs121918453 GRCh37 Chromosome 12, 112888198: 112888198
14 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
15 KIF1B NM_015074.3(KIF1B): c.3649C> T (p.Pro1217Ser) single nucleotide variant Likely pathogenic,risk factor rs121908163 GRCh37 Chromosome 1, 10406001: 10406001
16 KIF1B NM_015074.3(KIF1B): c.4442G> A (p.Ser1481Asn) single nucleotide variant Pathogenic,risk factor rs121908164 GRCh37 Chromosome 1, 10425534: 10425534
17 ALK NM_004304.4(ALK): c.3833A> C (p.Tyr1278Ser) single nucleotide variant Pathogenic rs863225285 GRCh38 Chromosome 2, 29209789: 29209789
18 ALK NM_004304.4(ALK): c.3734T> G (p.Phe1245Cys) single nucleotide variant Pathogenic rs863225283 GRCh38 Chromosome 2, 29213993: 29213993
19 ALK NM_004304.4(ALK): c.3733T> A (p.Phe1245Ile) single nucleotide variant Pathogenic/Likely pathogenic rs281864720 GRCh38 Chromosome 2, 29213994: 29213994
20 ALK NM_004304.4(ALK): c.3522C> G (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh38 Chromosome 2, 29220829: 29220829
21 ALK NM_004304.4(ALK): c.3522C> A (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh38 Chromosome 2, 29220829: 29220829
22 ALK NM_004304.4(ALK): c.3520T> C (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs281864719 GRCh38 Chromosome 2, 29220831: 29220831
23 ALK NM_004304.4(ALK): c.3520T> A (p.Phe1174Ile) single nucleotide variant Pathogenic rs281864719 GRCh38 Chromosome 2, 29220831: 29220831
24 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
25 ALK NM_004304.4(ALK): c.3735C> G (p.Phe1245Leu) single nucleotide variant Pathogenic rs863225284 GRCh38 Chromosome 2, 29213992: 29213992
26 ALK NM_004304.4(ALK): c.3521T> G (p.Phe1174Cys) single nucleotide variant Pathogenic rs1057519697 GRCh37 Chromosome 2, 29443696: 29443696
27 ALK NM_004304.4(ALK): c.3512T> A (p.Ile1171Asn) single nucleotide variant Pathogenic rs1057519698 GRCh37 Chromosome 2, 29445213: 29445213
28 MYC NM_002467.5(MYC): c.218C> T (p.Thr73Ile) single nucleotide variant Likely pathogenic rs756091827 GRCh37 Chromosome 8, 128750681: 128750681
29 ALK NM_004304.4(ALK): c.3824G> T (p.Arg1275Leu) single nucleotide variant Likely pathogenic rs113994087 GRCh37 Chromosome 2, 29432664: 29432664
30 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 GRCh37 Chromosome 8, 38274851: 38274851
31 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 GRCh37 Chromosome 8, 38275397: 38275397
32 MYC NM_002467.5(MYC): c.217A> C (p.Thr73Pro) single nucleotide variant Likely pathogenic rs750664148 GRCh37 Chromosome 8, 128750680: 128750680
33 MYC NM_002467.5(MYC): c.173C> T (p.Pro58Leu) single nucleotide variant Likely pathogenic rs1057519918 GRCh37 Chromosome 8, 128750636: 128750636
34 MYCN NM_005378.5(MYCN): c.131C> T (p.Pro44Leu) single nucleotide variant Likely pathogenic rs1057519919 GRCh37 Chromosome 2, 16082317: 16082317
35 PIK3CA NM_006218.3(PIK3CA): c.331A> G (p.Lys111Glu) single nucleotide variant Likely pathogenic rs1057519933 GRCh37 Chromosome 3, 178916944: 178916944
36 PIK3CA NM_006218.3(PIK3CA): c.333G> C (p.Lys111Asn) single nucleotide variant Likely pathogenic rs1057519934 GRCh37 Chromosome 3, 178916946: 178916946
37 PIK3CA NM_006218.3(PIK3CA): c.332A> G (p.Lys111Arg) single nucleotide variant Likely pathogenic rs1057519935 GRCh37 Chromosome 3, 178916945: 178916945
38 PTPN11 NM_002834.4(PTPN11): c.215C> A (p.Ala72Asp) single nucleotide variant Likely pathogenic rs121918454 GRCh37 Chromosome 12, 112888199: 112888199
39 TP53 NM_001126116.1(TP53): c.445G> T (p.Asp149Tyr) single nucleotide variant Likely pathogenic rs764146326 GRCh37 Chromosome 17, 7577097: 7577097
40 TP53 NM_001126116.1(TP53): c.445G> A (p.Asp149Asn) single nucleotide variant Likely pathogenic rs764146326 GRCh37 Chromosome 17, 7577097: 7577097
41 TP53 NM_001126117.1(TP53): c.447C> G (p.Asp149Glu) single nucleotide variant Likely pathogenic rs1057519984 GRCh37 Chromosome 17, 7577095: 7577095
42 TP53 NM_001126115.1(TP53): c.445G> C (p.Asp149His) single nucleotide variant Likely pathogenic rs764146326 GRCh37 Chromosome 17, 7577097: 7577097
43 TP53 NM_001126117.1(TP53): c.446A> C (p.Asp149Ala) single nucleotide variant Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
44 ALK NM_004304.4(ALK): c.3733T> C (p.Phe1245Leu) single nucleotide variant Likely pathogenic rs281864720 GRCh37 Chromosome 2, 29436860: 29436860
45 ALK NM_004304.4(ALK): c.3497T> G (p.Met1166Arg) single nucleotide variant Likely pathogenic rs1057520019 GRCh37 Chromosome 2, 29445228: 29445228

Copy number variations for Neuroblastoma from CNVD:

7 (show top 50) (show all 232)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13319 1 1 124300000 Amplification and lo ss Neuroblastoma
2 13325 1 1 124300000 Deletion Neuroblastoma
3 13344 1 1 125000000 Copy number Neuroblastoma
4 13349 1 1 125000000 Deletion Neuroblastoma
5 13355 1 1 125000000 Loss Neuroblastoma
6 13407 1 1 2300000 Copy number GNB1 Neuroblastoma
7 13408 1 1 2300000 Copy number SLC35E2 Neuroblastoma
8 13751 1 1 27800000 Loss Neuroblastoma
9 13762 1 1 28000000 Deletion Neuroblastoma
10 13837 1 10001852 10151200 Loss KIF1B Neuroblastoma
11 16476 1 125000000 249250621 Copy number CHD5 Neuroblastoma
12 16477 1 125000000 249250621 Copy number KIF1B Neuroblastoma
13 16597 1 128000000 247249719 Gain Neuroblastoma
14 16598 1 128000000 247249719 Gain Neuroblastoma
15 17283 1 142400000 148000000 Copy number NBPF23 Neuroblastoma
16 17374 1 142600000 147000000 Copy number NBPF1 Neuroblastoma
17 17375 1 142600000 147000000 Copy number NBPF15 Neuroblastoma
18 17376 1 142600000 147000000 Copy number NBPF3 Neuroblastoma
19 18773 1 147305744 147427061 Copy number NBPF Neuroblastoma
20 20614 1 153300000 247249719 Gain Neuroblastoma
21 20884 1 155000000 249250621 Gain Neuroblastoma
22 26022 1 195715155 196905060 Gain Neuroblastoma
23 27292 1 206429564 209469901 Gain Neuroblastoma
24 29290 1 2300000 12600000 Loss Neuroblastoma
25 29291 1 2300000 12600000 Loss Neuroblastoma
26 29292 1 2300000 12700000 Loss Neuroblastoma
27 32651 1 3815958 4146056 Amplification DFFB Neuroblastoma
28 32934 1 4056522 10472147 Loss Neuroblastoma
29 33588 1 46500000 51300000 Deletion Neuroblastoma
30 34972 1 5871399 5949729 Loss CHD5 Neuroblastoma
31 36107 1 7200000 16200000 Copy number Neuroblastoma
32 37032 1 84700000 88100000 Deletion Neuroblastoma
33 42798 10 40200000 135534747 Loss Neuroblastoma
34 43291 10 46100000 50100000 Gain Neuroblastoma
35 48305 11 1 10700000 Loss Neuroblastoma
36 48306 11 1 10700000 Loss Neuroblastoma
37 48334 11 1 2800000 Gain Neuroblastoma
38 49040 11 102400000 134452384 Deletion Neuroblastoma
39 49300 11 10515175 10701970 Amplification MRVI1 Neuroblastoma
40 49301 11 10515175 10701970 Amplification RNF141 Neuroblastoma
41 49302 11 10515175 10701970 Amplification XLKD1 Neuroblastoma
42 49698 11 110314720 118319416 Loss Neuroblastoma
43 50154 11 114581997 114912893 Loss CADM1 Neuroblastoma
44 51496 11 12700000 16200000 Copy number SOX6 Neuroblastoma
45 52328 11 16100000 21600000 Deletion Neuroblastoma
46 52785 11 19817525 19848438 Amplification NAV2 Neuroblastoma
47 52827 11 2043796 2201921 Amplification IGF2 Neuroblastoma
48 52828 11 2043796 2201921 Amplification INS Neuroblastoma
49 52829 11 2043796 2201921 Amplification TH Neuroblastoma
50 53355 11 2800000 10700000 Duplication LMO1 Neuroblastoma

Expression for Neuroblastoma

LifeMap Discovery
Genes differentially expressed in tissues of Neuroblastoma patients vs. healthy controls: 35 (show top 50) (show all 640)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 STAR steroidogenic acute regulatory protein Adrenal Gland - 9.57 0.000
2 CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 Adrenal Gland - 9.02 0.000
3 CYP11B1 cytochrome P450, family 11, subfamily B, polypeptide 1 Adrenal Gland - 8.90 0.000
4 CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1 Adrenal Gland - 8.90 0.000
5 ELAVL4 ELAV like neuron-specific RNA binding protein 4 Adrenal Gland + 8.22 0.000
6 SULT2A1 sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 Adrenal Gland - 8.16 0.000
7 HAND2 heart and neural crest derivatives expressed 2 Adrenal Gland + 8.05 0.000
8 STMN2 stathmin 2 Adrenal Gland + 7.76 0.000
9 PHOX2B paired-like homeobox 2b Adrenal Gland + 7.74 0.000
10 ISL1 ISL LIM homeobox 1 Adrenal Gland + 7.46 0.000
11 CYP21A2 cytochrome P450, family 21, subfamily A, polypeptide 2 Adrenal Gland - 7.45 0.000
12 MGST1 microsomal glutathione S-transferase 1 Adrenal Gland - 7.39 0.000
13 TUBB2B tubulin, beta 2B class IIb Adrenal Gland + 7.37 0.000
14 NPY neuropeptide Y Adrenal Gland + 7.34 0.000
15 GSTA1 glutathione S-transferase alpha 1 Adrenal Gland - 7.21 0.000
16 RTN1 reticulon 1 Adrenal Gland + 7.18 0.000
17 ADGRV1 adhesion G protein-coupled receptor V1 Adrenal Gland - 7.16 0.000
18 SCG2 secretogranin II Adrenal Gland + 7.15 0.000
19 DCX doublecortin Adrenal Gland + 7.06 0.000
20 NRK Nik related kinase Adrenal Gland - 7.01 0.000
21 MAB21L1 mab-21-like 1 (C. elegans) Adrenal Gland + 7.01 0.000
22 MRAP melanocortin 2 receptor accessory protein Adrenal Gland - 7.01 0.000
23 MGARP mitochondria-localized glutamic acid-rich protein Adrenal Gland - 6.97 0.000
24 SLC38A1 solute carrier family 38, member 1 Adrenal Gland + 6.95 0.000
25 RIMBP2 RIMS binding protein 2 Adrenal Gland + 6.84 0.000
26 CD24 CD24 molecule Adrenal Gland + 6.82 0.000
27 GNRHR gonadotropin-releasing hormone receptor Adrenal Gland - 6.80 0.000
28 LDLR low density lipoprotein receptor Adrenal Gland - 6.79 0.000
29 FDX1 ferredoxin 1 Adrenal Gland - 6.79 0.000
30 HMP19 HMP19 protein Adrenal Gland + 6.78 0.000
31 CPB1 carboxypeptidase B1 (tissue) Adrenal Gland - 6.76 0.000
32 CRMP1 collapsin response mediator protein 1 Adrenal Gland + 6.70 0.000
33 SOX11 SRY (sex determining region Y)-box 11 Adrenal Gland + 6.65 0.000
34 SYT1 synaptotagmin I Adrenal Gland + 6.61 0.000
35 GAP43 growth associated protein 43 Adrenal Gland + 6.61 0.000
36 TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 beta) Adrenal Gland + 6.59 0.000
37 SCN3A sodium channel, voltage gated, type III alpha subunit Adrenal Gland + 6.57 0.000
38 KRT1 keratin 1, type II Blood - 6.56 0.000
39 CELF4 CUGBP, Elav-like family member 4 Adrenal Gland + 6.53 0.000
40 CHGA chromogranin A Adrenal Gland + 6.45 0.000
41 ELAVL2 ELAV like neuron-specific RNA binding protein 2 Adrenal Gland + 6.41 0.000
42 SCARB1 scavenger receptor class B, member 1 Adrenal Gland - 6.33 0.000
43 IGFBPL1 insulin-like growth factor binding protein-like 1 Adrenal Gland + 6.17 0.000
44 INA internexin neuronal intermediate filament protein, alpha Adrenal Gland + 6.16 0.000
45 SNAP91 synaptosomal-associated protein, 91kDa Adrenal Gland + 6.16 0.000
46 CHRNA3 cholinergic receptor, nicotinic, alpha 3 (neuronal) Adrenal Gland + 6.16 0.000
47 PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 Adrenal Gland + 6.15 0.000
48 STMN4 stathmin-like 4 Adrenal Gland + 6.11 0.000
49 SIGLEC11 sialic acid binding Ig-like lectin 11 Adrenal Gland - 6.05 0.000
50 PDZK1IP1 PDZK1 interacting protein 1 Blood - 6.03 0.000
Search GEO for disease gene expression data for Neuroblastoma.

Pathways for Neuroblastoma

Pathways related to Neuroblastoma according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Neuroblastoma

Sources for Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....